CDKN2A/B HD have a direct oncogenic effect through loss of cell cycle inhibition and other parallel processes and are a molecular marker that influences grading and survival in IDH-mutant astrocytomas. This evidence concerns the gene CDKN2A and astrocytoma (excluding glioblastoma).